Imiglucerase, a special drug for type 1 Gaucher disease, has brought hope of life to countless patients with its unique pharmacological effects and precise medication instructions. This article will explore in depth what Imiglucerase is, its basic pharmacological effects and medication instructions, aiming to provide comprehensive and accurate information for patients and their families.
Imiglucerase Instructions
Imiglucerase, also known as Cerezyme, is a glucocerebrosidase analog produced by genetic recombination technology. It is an original drug produced by Sanofi Pharmaceuticals in France and has been launched in China. Imiglucerase exists in the form of lyophilized powder injection, mainly used to treat adults and children with type 1 Gaucher disease aged 2 years and above.
Ingredients and specifications
Imiglucerase is a glycoprotein containing 497 amino acids and 4 N-ring-linked glycosylation sites. Its specifications are usually 400U/10ml to ensure the accuracy and effectiveness of each medication.
Market and medical insurance information
Although Imiglucerase has been launched in China, it has not yet been included in the medical insurance catalogue, and patients need to purchase it at their own expense. This situation increases the economic burden on patients, but also highlights the importance of Imiglucerase in the treatment of Gaucher disease.
Imiglucerase is a specific drug for type 1 Gaucher disease. Its unique composition, specifications, and market and medical insurance information together form the basis for it to be the first choice for the treatment of Gaucher disease.
Basic pharmacological action of Imiglucerase
Imiglucerase mainly plays a role in the treatment of Gaucher disease by specifically catalyzing the hydrolysis of glucocerebroside, degrading it into glucose and ceramide.
Mechanism of action
Imiglucerase can replace the missing glucocerebrosidase in the patient's body, accelerate the metabolism and clearance of glucocerebroside, alleviate the patient's symptoms, and improve the quality of life.
Indications and targets
Imiglucerase is suitable for adults and children aged 2 years and above with type 1 Gaucher disease. Its applicable targets are not yet clear, but it has been proven to have significant efficacy in the treatment of Gaucher disease.
Through its unique pharmacological effects, Imiglucerase provides an effective treatment for patients with Gaucher disease, helping them to alleviate symptoms and improve their quality of life.
Imiglucerase medication instructions
When using Imiglucerase, patients should strictly follow the doctor's instructions and medication instructions to ensure the safety of medication.
Recommended dose and usage
Depending on the severity of the disease, the recommended dose of Imiglucerase ranges from 2.5U/kg three times a week to 60U/kg once every 2 weeks. Before medication, the dose should be titrated according to the patient's clinical manifestations and treatment goals. Imiglucerase does not contain preservatives and needs to be reconstituted and diluted using aseptic techniques and infused within the specified time.
Precautions and adverse reactions
During the use of Imiglucerase, patients should pay close attention to possible adverse reactions, such as back pain, chills, dizziness, fatigue, etc., and report to the doctor in a timely manner. At the same time, patients should be careful to avoid using it with other drugs at the same time, or consult a doctor before use to avoid potential interaction risks. For patients with anti-Imiglucerase antibodies, medication should be used with caution and antibody formation should be monitored regularly.
Correct medication guidance is the key to ensure that Imiglucerase can achieve the best therapeutic effect. Patients should strictly follow the doctor's guidance and medication instructions, reasonably adjust the dosage and usage, and pay close attention to adverse reactions and precautions to avoid danger.
